A Phase 3 Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2018
Price : $35 *
At a glance
- Drugs Somatrogon (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 21 Nov 2018 Planned End Date changed from 1 Dec 2021 to 1 Sep 2021.
- 21 Nov 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Sep 2020.
- 28 May 2018 New trial record